Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

NCT02921269 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02921269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02921269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2017
Completion date
January 13, 2021
Enrollment
11 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

cervical adenocarcinoma, cervical adenosquamous carcinoma, cervical squamous cell carcinoma, not otherwise specified, recurrent cervical carcinoma, stage iv cervical cancer ajcc v6 and v7, stage iva cervical cancer ajcc v6 and v7, stage ivb cervical cancer ajcc v6 and v7